ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer - EurekAlert

-
ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer  EurekAlert

Median time to treatment discontinuation (TTD) on crizotinib was 8.8 months; TTD of patients using entrectinib was 14.6 months. Compared with patients on ...



Comments

Post a Comment

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

-
Image
kathy lung cancer :: Article Creator Kathy Griffin Reveals Theory Her Lung Cancer Was Caused By Poisoning Kathy Griffin Reveals Theory Her Lung Cancer Was Caused by Poisoning SHARE SHARE TWEET SHARE EMAIL What to watch next Prince Harry Ghostwriter's Poorly Timed Swipe At Royals Newsweek Experts Say Russia Could Be In Trouble As Elites Look Escape 'Sinking Ship' Newsweek Jim Jordan's FBI Whistleblower Hearing Descends Into Chaos Newsweek Adidas Boycott Calls Grow Over Women's Swimsuit Modeled By Biological Male Newsweek General Testifies For House Armed Services Committee Newsweek Israeli Nationalist Gather For 'Flag March' In Jerusalem Newsweek Marjorie Taylor Greene Calls For Trump-Appointed FBI Director's Impeachment Newsweek Declawed Rescue Cat Dumped at Shelter Finally Gets A Name: 'Suits Him' Newsw...
Read more

Oncology: The disease, dynamics & challenges of market research

-
Image
inoperable small cell lung cancer :: Article Creator Inoperable Lung Cancer Inoperable lung cancer is a tumor that surgery can't treat. This might be because the cancer is in a hard-to-reach spot or for other reasons, like if it's spread outside your lungs. It's also called unresectable lung cancer. Just because you can't have surgery doesn't mean you can't do anything about the cancer. Treatments like radiation, chemotherapy, targeted therapy, and immunotherapy can fight it, even when an operation isn't an option. There are two main types of lung cancer, based on the size and other factors of the affected cells: Non-small-cell lung cancer (NSCLC). Up to 85% of lung cancer cases are this kind. It has three subtypes: Adenocarcinoma. This starts in cells that make things like mucus. It's often found in the outer parts of your lung, many times before it has spread. Squamous cell carcinoma. This begins in th...
Read more

Division of Continuing Professional Development

-
Image
invasive ductal cancer :: Article Creator ASTRO Updates Guidelines On Partial Breast Irradiation For Early Invasive Cancer The American Society for Radiation Oncology (ASTRO) updated their guidelines on partial breast irradiation (PBI) for patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). These new guidelines take into account results from multiple randomized controlled trials that have been published since ASTRO last issued recommendations for PBI in 2017. The trials included more than 10,000 women with about 10 years of follow-up, and, according to ASTRO guideline task force members, demonstrated "oncologic equivalence" between PBI and whole-breast irradiation (WBI) for the treatment of early-stage breast cancer and DCIS. "For patients with early-stage breast cancer, many are eligible for consideration of partial breast irradiation," Task Force Chair Janice Lyons, MD, of the Universi...
Read more